Boomerang Medical

Boomerang Medical is a clinical-stage medical device company pioneering a bioelectric neuromodulation therapy for autoimmune conditions, with an initial focus on Inflammatory Bowel Disease (IBD). Its lead technology has secured FDA Breakthrough Device Designation for Crohn's and ulcerative colitis and is currently being evaluated in an FDA-approved pivotal trial (BOOM-IBD2). The company is backed by leading venture capital firms, led by an experienced executive team with deep medtech expertise, and is positioned at the convergence of neurology and immunology within the emerging field of bioelectronic medicine.

Bioelectric neuromodulation device designed to stimulate specific nerves to modulate the immune system and reduce inflammation, focusing on the inflammatory reflex pathway.

Boomerang competes directly with large pharmaceutical companies developing advanced biologics and small molecules for IBD. It also faces potential competition from other bioelectronic medicine firms (e.g., SetPoint Medical, Galvani Bioelectronics) that may be targeting similar neural pathways for inflammatory diseases, though specific IBD programs are not widely publicized.